National and Kapodistrian University of Athens
Μελέτη ανοσολογικών μηχανισμών στην παθογένεια διάμεσων νοσημάτων του πνεύμονα
Abstract
dc:descriptionBackground: Lung cancer is prevalent in IPF, however there is still a lack of large databases. Given the prevalence of lung cancer in IPF and the paradigm of nintedanib repositioning, investigation of cancer-related pathways might have fruitful implications for patients with IPF. Aim/Methods: We aimed to create a registry for patients with IPF and lung cancer in Europe. Subsequently, we aimed to investigate cancer-related pathways in IPF. In particular, we investigated 1) the potential of SHP2 as anti-fibrotic mediator in vitro and 2) whether mediastinal lymphadenopathy in human and experimental lung fibrosis reflects specific immunologic activation and thus we focused on the expression of PD-1/PD-L1.Results: We identified 324 patients with lung cancer among 3178 patients with IPF (prevalence=10.2%). By the end of the 10 year-period following IPF diagnosis, 26.6% of alive patients with IPF had been diagnosed with lung cancer. Patients with IPF and lung cancer experienced increased risk of all-cause mortality than IPF patients without lung cancer [HR: 1.51, (95% CI: 1.22 to 1.86), p<0.0001]. Patients with IPF and lung cancer that received antifibrotics presented with decreased all cause-mortality compared to those who did not receive antifibrotics [HR: 0.61, (95% CI: 0.42 to 0.87), p=0.006]. In the adjusted model, a significantly lower proportion of surgically treated patients with IPF and otherwise technically operable lung cancer experienced all-cause mortality compared to non-surgically treated patients [HR: 0.30 (95% CI: 0.11 to 0.86), p=0.02].Primary mouse lung fibroblasts derived from mice carrying a conditional knockin mutation (D61G/+), rendering SHP2 catalytic domain constitutively active, had reduced proliferation (1.6-fold, p<0.05), migration (2-fold, p<0.05), as well as reduced responsiveness of TGFB-1 induced fibroblasts to myofibroblasts differentiation, compared to wild-type ones. An increased median PD-1% expression in lymphocytes derived from mediastinal lymph nodes of patients with IPF compared to lung cancer was observed. Tracheobronchial lymph nodes isolated on day 14 from bleomycin-treated mice exhibited increased size and higher PD-1 mRNA levels compared to saline-treated animals. Pembrolizumab blunted bleomycin-induced lung fibrosis, as indicated by reduction in Ashcroft score and improvement in respiratory mechanics. Conclusion: Lung cancer exerts a dramatic impact on patients with IPF. Investigation of cancer-related pathways in pulmonary fibrosis yielded fruitful results, given thatSHP2 attenuated fibrotic responses and PD-1 inhibition might be a novel therapeutic target in IPF.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karampitsakos, Theodoros
- Καραμπιτσάκος, Θεόδωρος
Subjects
dc:subject × 12- Ιδιοπαθής πνευμονική ίνωση
- Καρκίνος πνεύμονα
- Λεμφαδενοπάθεια μεσοθωρακίου
- Lung cancer
- Idiopathic pulmonary fibrosis (IPF)
- Mediastinal lymphadenopathy
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54353